Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors

Pharmacokinetic Study ◽

Kinase Inhibitor ◽

Advanced Solid Tumors ◽

Multiple Receptor ◽

Daily Oral Administration

A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-18-1881 ◽

2019 ◽

Vol 25 (18) ◽

pp. 5475-5484 ◽

Cited By ~ 6

Author(s):

Razelle Kurzrock ◽

Douglas W. Ball ◽

Marianna L. Zahurak ◽

Barry D. Nelkin ◽

Vivek Subbiah ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Phase I Trial ◽

Kinase Inhibitor ◽

Mek Inhibitor ◽

Vegf Receptor ◽

Advanced Solid Tumors ◽

Differentiated Thyroid Cancers

Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.2530 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 2530-2530 ◽

Cited By ~ 1

Author(s):

P. Witteveen ◽

M. Langenberg ◽

H. M. Verheul ◽

J. Roodhart ◽

M. Roelvink ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Solid Tumors ◽

Kinase Inhibitor ◽

Vegf Receptor ◽

Advanced Solid Tumors ◽

A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-07-1466 ◽

2008 ◽

Vol 14 (7) ◽

pp. 2075-2081 ◽

Cited By ~ 115

Author(s):

Debashis Sarker ◽

Rhoda Molife ◽

T.R. Jeffrey Evans ◽

Maryon Hardie ◽

Cheryl Marriott ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Solid Tumors ◽

Kinase Inhibitor ◽

Advanced Solid Tumors ◽

Receptor Tyrosine Kinase Inhibitor ◽

Pharmacodynamic Study

Corrections to “Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors”

Annals of Oncology ◽

10.1093/annonc/mdy532 ◽

2019 ◽

Vol 30 (6) ◽

pp. 1020 ◽

Cited By ~ 1

Author(s):

J.-C. Soria ◽

J. Cortes ◽

C. Massard ◽

J.-P. Armand ◽

D. De Andreis ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Solid Tumors ◽

Kinase Inhibitor ◽

Advanced Solid Tumors ◽

Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors

Annals of Oncology ◽

10.1093/annonc/mdq767 ◽

2011 ◽

Vol 22 (11) ◽

pp. 2508-2515 ◽

Cited By ~ 15

Author(s):

M.H.G. Langenberg ◽

P.O. Witteveen ◽

J. Roodhart ◽

M.P. Lolkema ◽

H.M.W. Verheul ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Solid Tumors ◽

Kinase Inhibitor ◽

Vegf Receptor ◽

Advanced Solid Tumors ◽

Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-010-1405-y ◽

2010 ◽

Vol 67 (5) ◽

pp. 1119-1128 ◽

Cited By ~ 11

Author(s):

Haruyasu Murakami ◽

Yutaka Ueda ◽

Tatsu Shimoyama ◽

Noboru Yamamoto ◽

Yasuhide Yamada ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Solid Tumors ◽

Kinase Inhibitor ◽

Receptor Tyrosine Kinase Inhibitor ◽

Biological Studies ◽

Multiple Receptor

108 POSTER Phase I study of ABT869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies.

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(06)70114-8 ◽

2006 ◽

Vol 4 (12) ◽

pp. 36 ◽

Cited By ~ 1

Author(s):

B.C. Goh ◽

C.H. Thang ◽

N. Sukri ◽

C.I. Wong ◽

R. Soo ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Phase I Study ◽

Kinase Inhibitor ◽

Receptor Tyrosine Kinase Inhibitor ◽

Solid Malignancies ◽

Multiple Receptor

A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-14-0409 ◽

2014 ◽

Vol 20 (24) ◽

pp. 6284-6294 ◽

Cited By ~ 18

Author(s):

L. Rhoda Molife ◽

Emma Jane Dean ◽

Montserrat Blanco-Codesido ◽

Matthew G. Krebs ◽

Andre T. Brunetto ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Solid Tumors ◽

Dose Escalation ◽

Kinase Inhibitor ◽

Advanced Solid Tumors ◽

Dose Escalation Study ◽

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors

Annals of Oncology ◽

10.1093/annonc/mdr137 ◽

2012 ◽

Vol 23 (2) ◽

pp. 463-471 ◽

Cited By ~ 13

Author(s):

J.-C. Soria ◽

J. Cortes ◽

C. Massard ◽

J.-P. Armand ◽

D. De Andreis ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Solid Tumors ◽

Kinase Inhibitor ◽

Advanced Solid Tumors ◽

A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-015-2899-0 ◽

2015 ◽

Vol 76 (6) ◽

pp. 1153-1161 ◽

Cited By ~ 24

Author(s):

Shinji Nakamichi ◽

Hiroshi Nokihara ◽

Noboru Yamamoto ◽

Yasuhide Yamada ◽

Kazunori Honda ◽

...

Keyword(s):

Tyrosine Kinase ◽

Solid Tumors ◽

Kinase Inhibitor ◽

Phase 1 ◽

Japanese Patients ◽

Advanced Solid Tumors ◽

Phase 1 Study ◽

Multiple Receptor